Related Posts
HSCA Comments on FDA Draft Guidance for Drug Supply Chain Security Act (DSCSA) Standards
November 9, 2022
On behalf of the Healthcare Supply Chain Association (HSCA), which represents the...
HSCA Comments on FDA “Risk Management Plans to Mitigate the Potential for Drug Shortages” Draft Guidance
August 22, 2022
On behalf of the Healthcare Supply Chain Association (HSCA), which represents the...
HSCA Response to FDA Notifying FDA of a Discontinuance or Interruption in Manufacturing of Finished Products or Active Pharmaceutical Ingredients Draft Guidance
June 5, 2023
On behalf of the Healthcare Supply Chain Association (HSCA), which represents the...
HSCA Comments to EPA on Proposal to Reduce Ethylene Oxide Emissions (EtO) from Commercial Sterilization Facilities and Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide
June 28, 2023
On behalf of the Healthcare Supply Chain Association (HSCA), we appreciate the...
HSCA Comments on FDA Draft Guidance for Drug Supply Chain Security Act (DSCSA) Standards
On behalf of the Healthcare Supply Chain Association (HSCA), which represents the nation’s leading healthcare group purchasing organizations (GPOs), we appreciate the opportunity to comment on the U.S. Food and Drug Administration’s (FDA’s) revised draft guidance, “DSCSA Standards for the Interoperable Exchange of Information for Tracing of Certain Human, Finished, Prescription Drugs Guidance for Industry.”
Click here to read the full comments.